Search
  • SBIJI Innovation

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease

- BX002 demonstrated safety and tolerability with successful delivery of a high concentration of viable phage to the lower gastrointestinal tract -

- First clinical study detailing pharmacokinetics of oral phage therapy under a U.S. FDA IND protocol -

- Efficacy results in reduction of target bacteria expected by mid-2022 from planned Phase 1b/2a study -


Read More

0 views

Recent Posts

See All

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved